Literature DB >> 9493642

Mechanisms of interferon beta action in multiple sclerosis.

S Dhib-Jalbut1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9493642     DOI: 10.1177/135245859700300609

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


× No keyword cloud information.
  6 in total

Review 1.  T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis.

Authors:  Kate O'Brien; Bruno Gran; Abdolmohamad Rostami
Journal:  Immunotherapy       Date:  2010-01       Impact factor: 4.196

Review 2.  Management of sight-threatening uveitis: new therapeutic options.

Authors:  Matthias D Becker; Justine R Smith; Regina Max; Christoph Fiehn
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Expression and functional significance of SOCS-1 and SOCS-3 in astrocytes.

Authors:  Hongwei Qin; Sandrine A Niyongere; Sun Jung Lee; Brandi J Baker; Etty N Benveniste
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

Review 4.  Cross-syndrome: myasthenia gravis and the demyelinating diseases of the central nervous system combination. Systematic literature review and case reports.

Authors:  Ekaterina Luzanova; Svetlana Stepanova; Nikita Nadtochiy; Elena Kryukova; Maria Karpova
Journal:  Acta Neurol Belg       Date:  2022-06-14       Impact factor: 2.396

Review 5.  Development of oral immunomodulatory agents in the management of multiple sclerosis.

Authors:  Richard Nicholas; Paolo Giannetti; Ali Alsanousi; Tim Friede; Paolo A Muraro
Journal:  Drug Des Devel Ther       Date:  2011-05-10       Impact factor: 4.162

Review 6.  Potential Risks and Benefits of Multiple Sclerosis Immune Therapies in the COVID-19 Era: Clinical and Immunological Perspectives.

Authors:  Vikram Bhise; Suhayl Dhib-Jalbut
Journal:  Neurotherapeutics       Date:  2021-02-02       Impact factor: 7.620

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.